Astrazeneca (AZN) Payables (2009 - 2026)

Astrazeneca has reported Payables for 18 years, with the latest figure at -$22.9 billion in Q2 2026.

• On a quarterly basis, Payables rose 4.56% year-over-year to -$22.9 billion in Q2 2026; TTM through Jun 2026 was -$22.9 billion, a 4.56% increase from a year earlier, with the FY2025 full-year figure at -$25.3 billion, down 12.29% from the prior year.
• Payables was -$22.9 billion for Q2 2026 at Astrazeneca, up from -$24.9 billion in the prior quarter.
• The five-year high for Payables was -$17.8 billion in Q2 2022, with the low at -$26.1 billion in Q3 2025.
• Average Payables over 5 years is -$21.6 billion, with a median of -$21.5 billion recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Payables retreated 17.89% in 2025, then grew 4.56% in 2026.
• Over 5 years, Payables stood at -$19.2 billion in 2022, then retreated by 17.45% to -$22.6 billion in 2023, then advanced by 0.23% to -$22.5 billion in 2024, then declined by 12.29% to -$25.3 billion in 2025, then climbed by 9.49% to -$22.9 billion in 2026.
• The last three Payables figures came in at -$22.9 billion (Q2 2026), -$24.9 billion (Q1 2026), and -$25.3 billion (Q4 2025), per Business Quant data.